These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19686788)

  • 21. Elastic liposome-mediated transdermal immunization enhanced the immunogenicity of P. falciparum surface antigen, MSP-119.
    Tyagi RK; Garg NK; Jadon R; Sahu T; Katare OP; Dalai SK; Awasthi A; Marepally SK
    Vaccine; 2015 Aug; 33(36):4630-8. PubMed ID: 26141014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gel core liposomes: an advanced carrier for improved vaccine delivery.
    Tiwari S; Goyal AK; Khatri K; Mishra N; Vyas SP
    J Microencapsul; 2009 Feb; 26(1):75-82. PubMed ID: 18608797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons.
    Kumar R; Nyakundi R; Kariuki T; Ozwara H; Nyamongo O; Mlambo G; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2013 Jun; 31(31):3140-7. PubMed ID: 23684840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.
    Lee SM; Wu CK; Plieskatt J; McAdams DH; Miura K; Ockenhouse C; King CR
    Malar J; 2016 Aug; 15(1):405. PubMed ID: 27515826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Datta D; Bansal GP; Gerloff DL; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Jan; 35(2):264-272. PubMed ID: 27912985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25.
    Scally SW; McLeod B; Bosch A; Miura K; Liang Q; Carroll S; Reponen S; Nguyen N; Giladi E; Rämisch S; Yusibov V; Bradley A; Lemiale F; Schief WR; Emerling D; Kellam P; King CR; Julien JP
    Nat Commun; 2017 Nov; 8(1):1568. PubMed ID: 29146922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission.
    Kapoor N; Vanjak I; Rozzelle J; Berges A; Chan W; Yin G; Tran C; Sato AK; Steiner AR; Pham TP; Birkett AJ; Long CA; Fairman J; Miura K
    Biochemistry; 2018 Feb; 57(5):516-519. PubMed ID: 29323879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes.
    Heidari Z; Arora JS; Datta D; John VT; Kumar N; Bansal GP
    Pharm Res; 2017 Sep; 34(9):1796-1804. PubMed ID: 28560696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.
    Pattnaik P; Shakri AR; Singh S; Goel S; Mukherjee P; Chitnis CE
    Vaccine; 2007 Jan; 25(5):806-13. PubMed ID: 17045706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres.
    Rosas JE; Pedraz JL; Hernández RM; Gascón AR; Igartua M; Guzmán F; Rodríguez R; Cortés J; Patarroyo ME
    Vaccine; 2002 Mar; 20(13-14):1707-10. PubMed ID: 11906756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based
    Singh SK; Plieskatt J; Chourasia BK; Fabra-García A; Garcia-Senosiain A; Singh V; Bengtsson KL; Reimer JM; Sauerwein R; Jore MM; Theisen M
    Front Immunol; 2020; 11():606266. PubMed ID: 33505395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL
    Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.
    Barr PJ; Green KM; Gibson HL; Bathurst IC; Quakyi IA; Kaslow DC
    J Exp Med; 1991 Nov; 174(5):1203-8. PubMed ID: 1940798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate.
    Gozar MM; Muratova O; Keister DB; Kensil CR; Price VL; Kaslow DC
    Exp Parasitol; 2001 Feb; 97(2):61-9. PubMed ID: 11281702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25.
    McLeod B; Miura K; Scally SW; Bosch A; Nguyen N; Shin H; Kim D; Volkmuth W; Rämisch S; Chichester JA; Streatfield S; Woods C; Schief WR; Emerling D; King CR; Julien JP
    Nat Commun; 2019 Sep; 10(1):4328. PubMed ID: 31551421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials.
    Zou L; Miles AP; Wang J; Stowers AW
    Vaccine; 2003 Apr; 21(15):1650-7. PubMed ID: 12639486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malaria transmission blocking activity of Anopheles stephensi alanyl aminopeptidase N antigen formulated with MPL, CpG, and QS21 adjuvants.
    Pourhashem Z; Nourani L; Pirahmadi S; Yousefi H; J Sani J; Raz A; Zakeri S; Dinparast Djadid N; Abouie Mehrizi A
    PLoS One; 2024; 19(7):e0306664. PubMed ID: 38968270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
    Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
    Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.